Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763

Article  PubMed  Google Scholar 

Early Breast Cancer Trialists’ Collaborative G (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–717. https://doi.org/10.1016/S0140-6736(05)66544-0

Article  CAS  Google Scholar 

Szymiczek A, Lone A, Akbari MR (2021) Molecular intrinsic versus clinical subtyping in breast cancer: a comprehensive review. Clin Genet 99:613–37. https://doi.org/10.1111/cge.13900

Article  CAS  PubMed  Google Scholar 

Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A (2021) Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel) 13. https://doi.org/10.3390/cancers13174287

Raghav KPS, Moasser MM (2022) Molecular pathways and mechanisms of HER2 in cancer therapy. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-22-0283

Sapino A, Goia M, Recupero D, Marchio C (2013) Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial ıssues. Front Oncol 3:129. https://doi.org/10.3389/fonc.2013.00129

Article  PubMed  PubMed Central  Google Scholar 

Oh DY, Bang YJ (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17:33–48. https://doi.org/10.1038/s41571-019-0268-3

Article  CAS  PubMed  Google Scholar 

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V et al (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519–30. https://doi.org/10.1016/S1470-2045(19)30863-0

Article  CAS  PubMed  Google Scholar 

Krop IE, Kim SB, Gonzalez-Martin A, LoRusso PM, Ferrero JM, Smitt M et al (2014) Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15:689–99. https://doi.org/10.1016/S1470-2045(14)70178-0

Article  CAS  PubMed  Google Scholar 

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med 382:610–21. https://doi.org/10.1056/NEJMoa1914510

Article  CAS  PubMed  Google Scholar 

Hanovich E, Asmis T, Ong M, Stewart D (2020) Rechallenge strategy in cancer therapy. Oncology 98:669–79. https://doi.org/10.1159/000507816

Article  CAS  PubMed  Google Scholar 

Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G et al (2012) Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer. Ann Oncol 23:1436–41. https://doi.org/10.1093/annonc/mdr474

Article  CAS  PubMed  Google Scholar 

Araki K, Fukada I, Horii R, Takahashi S, Akiyama F, Iwase T et al (2015) Trastuzumab rechallenge after lapatinib- and trastuzumab-resistant disease progression in HER2-positive breast cancer. Clin Breast Cancer 15:432–9. https://doi.org/10.1016/j.clbc.2015.06.002

Article  CAS  PubMed  Google Scholar 

Andre F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G et al (2023) Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 401:1773–85. https://doi.org/10.1016/S0140-6736(23)00725-0

Article  CAS  PubMed  Google Scholar 

Garcia-Alonso S, Ocana A, Pandiella A (2020) Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond. Trends Cancer 6:130–46. https://doi.org/10.1016/j.trecan.2019.12.010

Article  CAS  PubMed  Google Scholar 

Yang T, Fu Z, Zhang Y, Wang M, Mao C, Ge W (2020) Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer. Biomed Pharmacother 129:110465. https://doi.org/10.1016/j.biopha.2020.110465

Article  CAS  PubMed  Google Scholar 

Han Y, Wang J, Liu W, Yuan P, Li Q, Zhang P et al (2019) Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis. Cancer Manag Res 11:4699–706. https://doi.org/10.2147/CMAR.S198962

Article  CAS  PubMed  PubMed Central  Google Scholar